2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Familial hypercholesterolemia (FH) is the most common monogenic disorder. Due to the marked elevation of cardiovascular risk, the early detection, diagnosis, and proper management of this disorder are critical. Herein, the 2022 Korean guidance on this disease is presented. Clinical features include severely elevated low-density lipoprotein-cholesterol (LDL-C) levels, tendon xanthomas, and premature coronary artery disease. Clinical diagnostic criteria include clinical findings, family history, or pathogenic mutations in the LDLR, APOB, or PCSK9. Proper suspicion of individuals with typical characteristics is essential for screening. Cascade screening is known to be the most efficient diagnostic approach. Early initiation of lipid-lowering therapy and the control of other risk factors are important. The first-line pharmacological treatment is statins, followed by ezetimibe, and PCSK9 inhibitors as required. The ideal treatment targets are 50% reduction and <70 mg/dL or <55 mg/dL (in the presence of vascular disease) of LDL-C, although less strict targets are frequently used. Homozygous FH is characterized by untreated LDL-C >500 mg/dL, xanthoma since childhood, and family history. In children, the diagnosis is made with criteria, including items largely similar to those of adults. In women, lipid-lowering agents need to be discontinued before conception.
Abstract
Familial hypercholesterolemia (FH) is the most common monogenic disorder. Due to the marked elevation of cardiovascular risk, the early detection, diagnosis, and proper management of this disorder are critical. Herein, the 2022 Korean guidance on this disease is presented. Clinical features include severely elevated low-density lipoprotein-cholesterol (LDL-C) levels, tendon xanthomas, and premature coronary artery disease. Clinical diagnostic criteria include clinical findings, family history, or pathogenic mutations in the LDLR, APOB, or PCSK9. Proper suspicion of individuals with typical characteristics is essential for screening. Cascade screening is known to be the most efficient diagnostic approach. Early initiation of lipid-lowering therapy and the control of other risk factors are important. The first-line pharmacological treatment is statins, followed by ezetimibe, and PCSK9 inhibitors as required. The ideal treatment targets are 50% reduction and <70 mg/dL or <55 mg/dL (in the presence of vascular disease) of LDL-C, although less strict targets are frequently used. Homozygous FH is characterized by untreated LDL-C >500 mg/dL, xanthoma since childhood, and family history. In children, the diagnosis is made with criteria, including items largely similar to those of adults. In women, lipid-lowering agents need to be discontinued before conception.
참고문헌 (52)
- Austin MA, "Genetic causes of monogenic heterozygous familial hypercholesterolemia : a HuGE prevalence review", Am J Epidemiol, 160, pp.407~420 (2004)
- Benn M, "Mutations causative of familial hypercholesterolaemia : screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217", Eur Heart J, 37, pp.1384~1394 (2016)
- Lee SJ, "A case of familial hypercholesterolemia combined with diabetes mellitus", Korean J Med, 37, pp.558~564 (1989)
- You JH, "A case of familial hypercholesterolemia", J Korean Pediatr Soc, 32, pp.1288~1294 (1989)
- Mach F, "ESC committee for practice guidelines; ESC national cardiac societies. 2019 ESC", EAS guidelines for the management of dyslipidemias : lipid modification to reduce cardiovascular risk, 2019, pp.290, 140~205
- Harada-Shiba M, "Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017", J Atheroscler Thromb, 25, pp.751~770 (2018)
- Kim H, "Phenotypic and genetic analyses of Korean patients with familial hypercholesterolemia: results from the KFH registry 2020", J Atheroscler Thromb, pp.63062~ (2021)[DOI]
- Lee CJ, "Cardiovascular risk and treatment outcomes in severe hypercholesterolemia : a nationwide cohort study", J Am Heart Assoc, 11, pp.e024379~ (2022)
- Nordestgaard BG, "Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population : guidance for clinicians to prevent coronary heart disease : consensus statement of the European Atherosclerosis Society", Eur Heart J, 34, pp.3478~3490 (2013)
- Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63[DOI]
- Pérez de Isla L, "Predicting cardiovascular events in familial hypercholesterolemia : the SAFEHEART registry(Spanish familial hypercholesterolemia cohort study)", Circulation, 135, pp.2133~2144 (2017)
- Shin DG, "Clinical features of familial hypercholesterolemia in Korea : Predictors of pathogenic mutations and coronary artery disease – A study supported by the Korean Society of Lipidology and Atherosclerosis", Atherosclerosis, 243, pp.53~58 (2015)
- Schmidt EB, "Familial hypercholesterolaemia : history, diagnosis, screening, management and challenges", Heart, 106, pp.1940~1946 (2020)
- Harada-Shiba M, "Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan", J Atheroscler Thromb, 19, pp.1019~1026 (2012)
- Brunham LR, "Canadian cardiovascular society position statement on familial hypercholesterolemia : update 2018", Can J Cardiol, 34, pp.1553~1563 (2018)
- Starr B, "Development of sensitive and specific age-and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing", Clin Chem Lab Med, 46, pp.791~803 (2008)
- Sturm AC, "Clinical genetic testing for familial hypercholesterolemia JACC scientific expert panel", J Am Coll Cardiol, 72, pp.662~680 (2018)
- Tada H, "Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia", Eur Heart J, 38, pp.1573~1579 (2017)
- Chora JR, "The Clinical Genome Resource(ClinGen)Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification", Genet Med, 24, pp.293~306 (2022)
- Iacocca MA, "ClinVar database of global familial hypercholesterolemia-associated DNA variants", Hum Mutat, 39, pp.1631~1640 (2018)
- Han SM, "Genetic testing of Korean familial hypercholesterolemia using whole-exome sequencing", PLoS One, 10, pp.e0126706~ (2015)
- Rader DJ, "Disorders of lipoprotein metabolism" (2018), McGraw-Hill Education LLC
- Tada H, "Diagnosis and management of sitosterolemia 2021", J Atheroscler Thromb, 28, pp.791~801 (2021)
- Brahm AJ, "Combined hyperlipidemia : familial but not(usually)monogenic", Curr Opin Lipidol, 27, pp.131~140 (2016)
- Cuchel M, "Homozygous familial hypercholesterolemia : new insight and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolemia of the European Atherosclerosis Society", Eur Heart J, 352, pp.2146~2157 (2014)
- Representatives of the Global Familial Hypercholesterolemia Community, "Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action", JAMA Cardiol, 5, pp.217~229 (2020)
- 이은정, "2018 Guidelines for the Management of Dyslipidemia in Korea", 지질·동맥경화학회지, 8(2), pp.78~131 (2019), 한국지질동맥경화학회[DOI]
- Raal FJ, "Familial hypercholesterolemia treatments : guidelines and new therapies", Atherosclerosis, 277, pp.483~492 (2018)
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Oh J, "Target achievement with maximal statin-based lipidlowering therapy in Korean patients with familial hypercholesterolemia : a study supported by the Korean Society of Lipid and Atherosclerosis", Clin Cardiol, 40, pp.1291~1296 (2017)
- Kim H, "GENetic characteristics and REsponse to lipidlowering therapy in familial hypercholesterolemia : GENRE-FH study", Sci Rep, 10, pp.19336~ (2020)
- Versmissen J, "Efficacy of statins in familial hypercholesterolaemia : a long term cohort study", BMJ, 337, pp.a2423~ (2008)
- Besseling J, "Statins in familial hypercholesterolemia : consequences for coronary artery disease and all-cause mortality", J Am Coll Cardiol, 68, pp.252~260 (2016)
- Baigent C, "Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170, 000 participants in 26randomised trials", Lancet, 376, pp.1670~1681 (2010)
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
- Tsujita K, "Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention : the multicenter randomized controlled PRECISE-IVUS trial", J Am Coll Cardiol, 66, pp.495~507 (2015)
- Kim Kihyun, "Comparison of the Effects of Highintensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study", 지질·동맥경화학회지, 10(3), pp.291~302 (2021), 한국지질동맥경화학회[DOI]
- Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
- Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
- Landmesser U, "2017 update of ESC", EAS Task Force on practical clinical guidance for proprotein convertase subtilisin, Eur Heart J, pp.2018, 39[DOI]
- Nohara A, "Statement for appropriate clinical use of PCSK9 inhibitors", J Atheroscler Thromb, 25, pp.747~750 (2018)
- Raal FJ, "Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia : a randomised, double-blind, placebo-controlled trial", Lancet, 375, pp.998~1006 (2010)
- Cuchel M, "Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia : a single-arm, open-label, phase 3 study", Lancet, 381, pp.40~46 (2013)
- Raal FJ, "Inclisiran for the treatment of heterozygous familial hypercholesterolemia", N Engl J Med, 382, pp.1520~1530 (2020)
- Rosenson RS, "Evinacuamb in patients with refractory hypercholesterolemia", N Engl J Med, 383, pp.2307~2319 (2020)
- Raal FJ, "Evinacumab for homozygous familial hypercholesterolemia", N Engl J Med, 383, pp.711~720 (2020)
- EAS Familial Hypercholesterolaemia Studies Collaboration(FHSC), "Global perspective of familial hypercholesterolaemia : a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration(FHSC)", Lancet, 398, pp.1713~1725 (2021)
- Santos RD, "Defining severe familial hypercholesterolaemia and the implications for clinical management : a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel", Lancet Diabetes Endocrinol, 4, pp.850~861 (2016)
- Gidding SS, "The agenda for familial hypercholesterolemia : a scientific statement from the American Heart Association", Circulation, 132, pp.2167~2192 (2015)
- Wiegman A, "Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment", Eur Heart J, 36, pp.2425~2437 (2015)
- Santos RD, "Evolocumab in pediatric heterozygous familial hypercholesterolemia", N Engl J Med, 383, pp.1317~1327 (2020)
- Graham DF, "Management of familial hypercholesterolemia in pregnancy", Curr Opin Lipidol, 32, pp.370~377 (2021)